What Clarithromycin - 1 A Pharma Treats: Main Uses and Benefits

Clarithromycin is an antibiotic commonly used across conditions presenting with acute episodes and symptoms related to systemic imbalance, where the medication is considered relevant for use across several major therapeutic areas.

These therapeutic areas include conditions that cause noticeable physiological strain, such as those often associated with lower respiratory tract symptoms (e.g., in cases of pneumonia or acute bronchitis), conditions related to upper respiratory tract symptoms (e.g., pharyngitis, sinusitis), as well as conditions involving skin and soft tissue symptoms (e.g., cellulitis or erysipelas). It is also commonly used in situations involving duodenal ulcers where H. pylori bacteria is linked, helping to ease the overall symptom burden. This medicine may assist with managing symptoms that interfere with daily comfort, supporting general well-being during symptomatic phases.

“The medicine is commonly used across conditions presenting with acute episodes and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Support During Acute Symptoms
Clarithromycin is applied in clinical settings that involve acute or unstable symptom patterns associated with bacterial infections and may assist with easing the overall symptom burden.

Official Regulatory Eligibility Summary

Clarithromycin - 1 A Pharma tablets are generally indicated for use in adults and adolescents aged 12 years and older. The tablets are not recommended for children under 12; a paediatric suspension formulation should be used instead.

Use is strictly contraindicated for several key populations and under specific conditions, primarily due to the risk of serious cardiac or metabolic events. This medicine must not be used by patients who:

• Have a known allergy or hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.
• Have a history of QT prolongation (a heart rhythm disorder) or ventricular cardiac arrhythmia.
• Have severe hepatic failure combined with renal impairment.
• Have an uncorrected electrolyte disturbance, such as low potassium (hypokalaemia) or low magnesium (hypomagnesaemia).
• Are taking certain medications that interact dangerously, including the statins lovastatin and simvastatin, ergot alkaloids (e.g., ergotamine), colchicine (especially with renal/hepatic impairment), or cardiac/antihistamine drugs such as cisapride, pimozide, astemizole, or terfenadine.

For pregnant women, use is not recommended unless the prescribing physician determines that no suitable alternative exists and the benefit clearly outweighs the potential risk. Caution is advised for patients with existing moderate liver or kidney problems.

Interactions with other medicines and products

Clarithromycin interacts with a wide range of medicinal products, primarily due to its documented effect as a strong inhibitor of the CYP3A4 enzyme. This metabolic inhibition significantly increases the plasma concentration and overall exposure of numerous co-administered drugs by reducing their clearance.

The regulatory profile outlines specific drug combinations that are strictly prohibited:

Interaction Classification	Interacting Agents	Risk / Outcome
Contraindicated Combinations	Astemizole, Cisapride, Pimozide, Terfenadine, Domperidone	Risk of severe QT prolongation and Torsades de Pointes.
	Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine)	Risk of acute ergot toxicity, including vasospasm.
	Lovastatin, Simvastatin	Risk of myopathy and rhabdomyolysis. Suspension of statin therapy is mandatory during Clarithromycin treatment.

Other clinically significant interactions require careful monitoring. Co-administration with drugs like Digoxin or Theophylline can lead to elevated serum concentrations. The profile also notes additive risks, such as a potentially potentiated anticoagulant effect when used with Warfarin, which requires intensive monitoring of the International Normalized Ratio (INR). Furthermore, the official labeling notes the interaction with Colchicine is explicitly contraindicated in patients who have pre-existing renal or hepatic impairment. The ingestion of food slightly increases the peak concentration of the immediate-release tablet.

Clarithromycin exerts its action as an allosteric inhibitor primarily targeting the 50S ribosomal subunit—the protein construction site of susceptible bacteria. The drug binds specifically to the 23S ribosomal RNA component, resulting in translational arrest by physically blocking the exit tunnel for the nascent polypeptide chain. This halt in the synthesis of essential proteins leads to bacteriostasis, a state of arrested growth that facilitates the host's immune system clearance of the non-replicating pathogens.

The macrolide mechanism is constrained biologically by defenses like drug efflux (pumping the drug out) and target site modification (altering the 50S subunit), which limit its inhibitory impact. Additionally, Clarithromycin exhibits a secondary mechanistic domain by modulating host physiological responses. It alters pro-inflammatory signaling within host tissues by modulating the production of certain cytokine molecules, influencing the local host-mediated response.

The use of Clarithromycin - 1 A Pharma is governed by official prescribing information that dictates the route, frequency, and specific administration conditions. It is approved for oral administration as tablets (immediate- or extended-release) and a reconstituted suspension, or for intravenous (IV) infusion in hospital settings when oral administration is not suitable.

Administration Dosing and Frequency

Form	Standard Adult Dose	Frequency
Immediate-Release (IR)	250 mg to 500 mg	Twice Daily (q12hr)
Extended-Release (XL)	1000 mg	Once Daily (q24hr)

The typical course duration ranges from 7 to 14 days, though treatment for infections caused by Streptococcus species requires a minimum duration of 10 days.

Key Usage Conditions

• Food Intake: Extended-release (XL) tablets must be taken with food, while immediate-release forms may be taken independently of meals.
• Dose Integrity: XL tablets must be swallowed whole and must not be crushed, chewed, or broken, as this interferes with the controlled-release mechanism.
• Pediatric Dosing: For children 6 months and older, the dose is calculated by body weight, typically 7.5 mg/ kg every 12 hours, using the oral suspension.
• Renal Adjustment: The total daily dose must be reduced by one-half in adults with significant renal impairment (creatinine clearance < 30 mL/ min) to prevent drug accumulation.

Procedural Summary

Clarithromycin is administered orally or intravenously under strict regulatory constraints concerning the correct timing, physical handling of the dosage form, and necessary dose modifications based on the patient's physiological status.

Research Evidence / Overview of Studies for Clarithromycin - 1 A Pharma

This overview summarizes the type of research that has been conducted on the medicine, focusing on what patient groups and outcomes were studied and what aspects of the evidence remain uncertain. Studies help show what has been observed so far, but research provides context but not individual predictions for personal outcomes.

---

Evidence for Infections of the Lungs and Airways

Research exploring how symptoms change over time in conditions like Community-Acquired Pneumonia (CAP) and acute bronchitis has included both short-term Randomized Controlled Trials (RCTs) and larger observational cohort studies. These trials primarily were studied for how the medicine was observed in adults with mild-to-moderate infections. The primary outcomes research examined included the measurement of changes in clinical status and the rate of bacterial clearance (microbiological eradication).

Long-term effects are not fully established based on the observation periods of certain cohort studies. The evidence is challenged by the global and regional variability in bacterial resistance to macrolides, which was observed in some studies to affect the findings.

---

Evidence for Infections of the Sinuses, Throat, and Skin

Research has explored how the medicine was observed in upper respiratory tract infections (URTIs) and infections of the skin, such as cellulitis. The primary outcomes research examined were primarily outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort. Follow-up durations were limited primarily to the acute treatment window, meaning there is limited information for long-term outcomes or the durability of the response against these infections.

---

Evidence for Helicobacter pylori Eradication Regimens

The medicine was observed in studies as a component of the Classic Triple Therapy, a multi-drug regimen relevant in trials related to peptic ulcer disease caused by the H. pylori bacterium. The crucial outcome research examined was the H. pylori Eradication Rate, which is assessed approximately one month after completing the course. The central uncertainty is the widespread, rising clarithromycin resistance across many global regions, where evidence suggests observed outcomes can be inconsistent.

---

Evidence in Children and Other Specific Groups

Clarithromycin was evaluated in specific trials designed for pediatric patients (typically children aged 6 months to 12 years) using the oral suspension formulation. Research also was observed in older adults through large observational settings evaluating daily-life functioning. Data for certain groups remain insufficient, especially for patients with complex, co-occurring functional limitations or severe systemic illness. Information regarding vulnerable populations is primarily derived from observational research where certainty remains low.

---

What Research Gaps and Uncertainties Remain

The evidence indicates that the rise of antibiotic resistance in common pathogens is the primary complication, as this means the success rate documented in older trials may not reflect current real-world outcomes in all regions. Additionally, certain observational studies have suggested that macrolide use was associated with specific, rare cardiovascular outcomes in the short term. The long-term effects are not fully established, and research is ongoing to contextualize this finding within the overall body of evidence.

Key Studies & References Clinical experience with clarithromycin for the treatment of respiratory tract infections

Common questions about Clarithromycin - 1 A Pharma (FAQ)

---

Q: What happens if I forget to take a dose of Clarithromycin - 1 A Pharma?

Official instructions describe that a missed dose is generally taken as soon as it is remembered. However, if the time is very close to the next scheduled dose, the missed dose is typically skipped entirely. The patient then continues with the regular dosing schedule and does not double the dose to make up for the missed one.

---

Q: Is it necessary to finish the entire course of Clarithromycin - 1 A Pharma even if I feel better?

The official prescribing information indicates that for the treatment of certain infections, such as those caused by Streptococcus species, a minimum duration of treatment is required. Completing the full duration described in the official treatment plan is intended to aid in the complete eradication of the pathogen and help reduce the potential for the infection to return.

---

Q: What are the serious signs or symptoms related to liver issues that are associated with Clarithromycin - 1 A Pharma?

Official regulatory documents list signs of potential liver injury that may require urgent medical attention. These signs can include jaundice (yellowing of the skin or eyes), unusual tiredness, very dark urine, or significant abdominal pain. The medication carries a warning regarding the potential for severe liver toxicity.

---

Q: Is a metallic or strange taste in the mouth normal when taking this medicine?

Yes, official safety data lists taste disturbance as a Common adverse reaction, meaning it may affect up to 1 in 10 people. This side effect is often described by patients as a metallic or otherwise altered taste perception in the mouth.

---

Q: Can Clarithromycin - 1 A Pharma be taken if someone has kidney problems?

Official prescribing documents indicate that the medicine's use requires caution in patients with moderate-to-severe kidney impairment. The labeling notes that a modification to the prescribed amount is typically required for adults with significant renal impairment to prevent drug accumulation.

---

Q: Why do some people experience stomach upset with Clarithromycin - 1 A Pharma?

As a macrolide antibiotic, the medicine may cause gastrointestinal upset, such as nausea or diarrhea. This is often due to the macrolide class's known effect on gut motility (how quickly food moves through the digestive system) and its impact on the natural gut flora.

---

Q: What is the risk of antibiotic resistance when using Clarithromycin - 1 A Pharma?

Regulatory documents include warnings that this drug should only be used to treat infections proven or strongly suspected to be caused by susceptible bacteria. This practice is emphasized to help limit the public health risk associated with the development of antibiotic resistance.

---

Q: Why do some sources state that Clarithromycin - 1 A Pharma should not be used in people with certain heart rhythm problems?

The medicine is strictly contraindicated (meaning its use is prohibited) for patients with a known history of certain heart conditions, such as QT prolongation or ventricular cardiac arrhythmia. This is due to the risk of severe cardiac events associated with the drug.

---

Q: Does the efficacy of Clarithromycin - 1 A Pharma change if taken with or without food?

Official regulatory documents specify that the extended-release (XL) tablets must be taken with food. However, the immediate-release (IR) tablets may be taken independently of meals, although food may still slightly affect the absorption of the IR form.

---

Q: Does Clarithromycin - 1 A Pharma interact with grapefruit or grapefruit juice?

Yes, official drug interaction information indicates that grapefruit and grapefruit juice can inhibit the metabolism of the drug. This effect may lead to an increase in the medicine's concentration in the body, potentially increasing the risk of adverse effects.

---

Q: Can Clarithromycin - 1 A Pharma cause trouble sleeping?

Insomnia (difficulty falling or staying asleep) is listed as a Common adverse reaction in the official safety profile. As a result, the medicine is known to cause trouble sleeping in some patients.

---

Q: How long does Clarithromycin - 1 A Pharma stay in the body after the last pill?

The rate at which the drug is eliminated from the body is indicated by its half-life—the time it takes for the concentration of the drug to decrease by half. Official product information describes this half-life, which shows the medicine is steadily cleared from the body over time.

---

Q: Is it true that Clarithromycin - 1 A Pharma can cause temporary hearing loss?

Regulatory documents list hearing loss as an Uncommon adverse reaction, meaning it may affect up to 1 in 100 people. Some medical reports suggest that this effect may be reversible and resolve upon stopping the medication.

---

Q: Is it safe to drive or operate machinery while taking Clarithromycin - 1 A Pharma?

Official labeling advises that the medicine may cause side effects such as dizziness, confusion, or visual changes. These types of effects could affect a person's ability to drive safely or operate machinery, and caution is noted in the prescribing information.

---

Q: What should be done if an allergic reaction is suspected?

Regulatory warnings indicate that serious allergic reactions (including anaphylaxis) are possible with this medicine. If a serious allergic reaction is suspected, the regulatory guidance is that the medicine is immediately discontinued and urgent medical attention is sought.

---

Q: Can a person become dependent on Clarithromycin - 1 A Pharma?

The medicine is a macrolide antibiotic and is not classified as a controlled substance by regulatory bodies. Therefore, it is not associated with the potential for drug dependence or addiction.

---

Q: How is the safety of Clarithromycin - 1 A Pharma described for breastfeeding mothers?

Official labels state that the medicine and its active metabolite can pass into human breast milk. For this reason, caution is advised, and breastfeeding is not recommended while using this medicine, according to some regulatory documents.

---

Q: Why is Clarithromycin - 1 A Pharma used in combination with other drugs for certain treatments?

For specific treatments, such as the eradication of Helicobacter pylori, the medicine is used as a component of a multi-drug regimen. This combination approach is used to enhance the overall effectiveness and help overcome bacterial resistance.

---

Q: Why is it described that Clarithromycin - 1 A Pharma may prolong the QT interval?

As a member of the macrolide antibiotic class, the medicine can affect the electrical conduction pathways in the heart muscle cells. This effect can sometimes be observed as a change in the heart rhythm called a prolonged QT interval on an electrocardiogram.

---

Q: Does Clarithromycin - 1 A Pharma affect the results of any lab tests?

The medicine may interfere with the results of certain laboratory tests, specifically those used to measure the levels of co-administered drugs like Digoxin or Theophylline in the blood. This interference can lead to falsely elevated readings.

---

Q: Do regulatory bodies impose any special monitoring requirements for patients using Clarithromycin - 1 A Pharma?

Official labeling states that intensive monitoring of the International Normalized Ratio (INR) is typically recommended or indicated when the drug is co-administered with anticoagulants like warfarin. Drug levels may also require monitoring for other co-administered medications.

---

Q: Is it possible to develop a secondary infection, like thrush, while on Clarithromycin - 1 A Pharma?

Official warnings note that, like other antibiotics, prolonged or repeated use may result in the overgrowth of non-susceptible bacteria or fungi. This imbalance can potentially lead to a secondary infection.

Storage and Disposal of Clarithromycin

Official regulatory information defines specific storage rules based on the product form. All forms must be stored out of the sight and reach of children.

---

Storage Requirements

Clarithromycin tablets must be stored at room temperature (20 C to 25 C) in their original, tightly closed container and protected from light.

Clarithromycin Oral Suspension (mixed liquid) must be stored between 15 C and 30 C. It must not be refrigerated or frozen. The suspension must be discarded after 14 days of preparation.

---

Disposal

Unused or expired product must be disposed of safely. Disposal must be carried out in accordance with local requirements for unused medicines, and the product must not be thrown away via wastewater or household waste.